CLP1: A Potential Drug Target and Biomarker for the Homolog of Yeast CFIA Subunit Clp1p

Target Name: CLP1

NCBI ID: G10978

CLP1

CLP1: A Potential Drug Target and Biomarker for the Homolog of Yeast CFIA Subunit Clp1p

The Clp1 gene, located on chromosome X of the yeast species Saccharomyces cerevisiae, encodes for a protein known as Clp1p. Clp1p is a member of the CFIA (Citrate synthase enzyme I) subunit family, which is responsible for catalyzing the final step of the citric acid cycle, a critical metabolic pathway for the production of energy in eukaryotic cells. The deletion or mutation of the Clp1 gene has been observed to result in a range of cellular and biochemical changes, including increased sensitivity to inhibitors, growth inhibition, and altered cell wall structure.

Recent studies have identified CLP1p as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is due to its involvement in various cellular processes that are crucial for the normal function of cells, as well as its potential to modulate cellular signaling pathways.

Drug Targets and Biomarkers

Several drug compounds have been shown to interact with or inhibit the activity of Clp1p. One of these drugs, CLP1p inhibitors, has been shown to have therapeutic potential in various diseases. For example, CLP1p inhibitors have been shown to be effective in treating neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by modulating the activity of Clp1p and preventing the accumulation of beta-amyloid peptides and neurofibrillary tangles in the brain.

Another potential application of CLP1p inhibitors is in cancer treatment. The production of reactive oxygen species (ROS) is a well-established mechanism of cancer promotion, and the use of CLP1p inhibitors has been shown to inhibit ROS production and reduce the sensitivity of cancer cells to chemotherapy. This may lead to a more effective treatment of cancer by reducing the risk of side effects and increasing the overall effectiveness of the drug.

In addition to its potential therapeutic applications, CLP1p has also been identified as a potential biomarker for various diseases. The production of Clp1p is affected by various cellular signaling pathways, including the TOR signaling pathway. This means that changes in the production or activity of Clp1p can be an indication of cellular stress or dysfunction.

Research on the Clp1 gene has also shown that it is involved in the regulation of cell wall structure and integrity. The cytosol is the fluid inside the cell that surrounds the cell membrane and is responsible for maintaining the structural integrity of the cell wall. The cytosol is derived from the intercellular space and is continuously replaced by new cytosol through the process of endocytosis. The activity of Clp1p has been shown to be involved in regulating the production and degradation of cytosol, which may be related to the regulation of cell wall structure and integrity.

Conclusion

In conclusion, CLP1p is a gene that has been identified as a potential drug target and biomarker for various diseases. Its involvement in various cellular processes, including the TOR signaling pathway and the regulation of cytosol production, makes it an attractive target for drug development. Further research is needed to fully understand the functions of CLP1p and its potential as a drug and biomarker.

Protein Name: Cleavage Factor Polyribonucleotide Kinase Subunit 1

Functions: Polynucleotide kinase that can phosphorylate the 5'-hydroxyl groups of double-stranded RNA (dsRNA), single-stranded RNA (ssRNA), double-stranded DNA (dsDNA) and double-stranded DNA:RNA hybrids. dsRNA is phosphorylated more efficiently than dsDNA, and the RNA component of a DNA:RNA hybrid is phosphorylated more efficiently than the DNA component. Plays a key role in both tRNA splicing and mRNA 3'-end formation. Component of the tRNA splicing endonuclease complex: phosphorylates the 5'-terminus of the tRNA 3'-exon during tRNA splicing; this phosphorylation event is a prerequisite for the subsequent ligation of the two exon halves and the production of a mature tRNA (PubMed:24766809, PubMed:24766810). Its role in tRNA splicing and maturation is required for cerebellar development (PubMed:24766809, PubMed:24766810). Component of the pre-mRNA cleavage complex II (CF-II), which seems to be required for mRNA 3'-end formation. Also phosphorylates the 5'-terminus of exogenously introduced short interfering RNAs (siRNAs), which is a necessary prerequisite for their incorporation into the RNA-induced silencing complex (RISC). However, endogenous siRNAs and microRNAs (miRNAs) that are produced by the cleavage of dsRNA precursors by DICER1 already contain a 5'-phosphate group, so this protein may be dispensible for normal RNA-mediated gene silencing

The "CLP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets